Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience’s second human pilot study shows its DehydraTECH-processed Rybelsus capsules are well-tolerated with zero adverse events, outperforming the commercially available Rybelsus tablets, which showed higher instances of mild and moderate adverse effects. The study suggests that DehydraTECH technology may improve the delivery of semaglutide, potentially reducing side effects for users.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
